冠状动脉介入术患者服用氯吡格雷剂量、基因多态性、血小板聚集率和临床预后的关联性研究
|
摘要
一、研究背景
氯吡格雷作为血小板膜蛋白P2Y12受体的抑制剂,通过阻断其与二磷酸腺苷(ADP)的结合发挥抑制血小板聚集作用。该药与阿司匹林联合应用,预防冠状动脉粥样硬化性心脏病(冠心病,CHD)患者接受了经皮冠状动脉介入治疗(PCI)术后的心脏缺血性事件复发,已成为目前美国、欧洲及我国指南共同推荐的常规治疗策略。
近年的研究表明,这种双联抗血小板的治疗策略尚不能完全避免冠状动脉支架植入术后心脏缺血性事件的发生,其剩余风险可能与抗血小板药物的个体反应性,特别是氯吡格雷的个体间差异存在一定程度的关联。
目前已知一种由CYP2C19基因编码的代谢酶,在氯吡格雷经肝脏代谢转化为活性产物的过程中发挥着至关重要的作用。携带该功能丧失性等位基因的患者表现为对氯吡格雷反应性不佳,成为PCI术后支架内血栓形成及主要心血管不良事件发生的一个重要因素。血小板功能检测结果作为抗血小板药物疗效的一种表现形式,与CYP2C19基因型一并成为评价个体对氯吡格雷反应性的指标,在临床研究中作为个体化治疗策略调整的依据被广泛采用。然而,近期数个依据血小板活性对患者进行分组并给予不同治疗方案的前瞻性临床研究却未能取得预期的阳性结果。
本研究拟以血小板聚集率为指标,评价CYP2C19基因型、不同剂量的氯吡格雷预处理策略和PCI介入操作本身对该指标的影响,了解其各自之间的关联性；并以冠状动脉支架植入术后心血管事件和出血事件的发生率为指标,评价根据CYP2C19的基因型或血小板聚集率的表现型两种分组方式对患者远期预后的预测价值,为进一步寻找最佳的氯吡格雷治疗模式提供相应的理论依据。
二、研究内容及结果
第一部分不同氯吡格雷预处理剂量CYP2C19基因型对冠心病患者PCI术前血小板聚集率、术后心肌酶学指标的影响
1.研究目的
评价PCI术前两种不同的氯吡格雷预处理策略：未曾服用该药的患者接受300mg负荷剂量,对比已长期服用该药75mg每日一次的维持剂量,在不同CYP2C19基因型的CHD患者中是否存在血小板抑制作用的差异。
2.研究方法
2.1研究对象：连续入选2012年5月至2013年5月间在阜外心血管病医院住院,并拟接受PCI治疗的CHD患者。入院前已连续服用氯吡格雷(波利维)75mg/日持续7天以上(维持剂量组),或未曾服用过氯吡格雷(负荷剂量组)。
2.2CYP2C19基因型检测：采用Taqman(?)技术在全部患者中进行,测量位点包括CYP2C19*2、CYP2C19*3、CYP2C19*17。除外*17携带者后,依患者是否携带*2或*3任一功能丧失性(LOF)等位基因,将其分为携带者组与非携带者组。2.3血小板功能检测：负荷剂量组患者在服用300mg氯吡格雷后12小时,维持剂量组患者在上一次服用75mg氯吡格雷后24小时进行空腹采血,以ADP (10umol/L)诱导激活的光学比浊法对血小板聚集率进行测定。
2.4依据上述氯吡格雷预处理策略和CYP2C19基因型两种方式对患者进行两两分组,比较在全部患者中PCI术前的血小板聚集率、以及在接受冠状动脉支架植入患者中术后的心肌酶学指标(cTNI和CK-MB)在不同组间是否存在差异。
3.研究结果
3.1在全部入选的840例患者中,根据氯吡格雷的预处理策略(负荷剂量组470例,维持剂量组370例),以及CYP2C19基因型(CYP2C19*2或*3LOF等位基因携带者494例,非携带者346例)进行了两两分组及进一步的2×2分组。
3.2接受负荷剂量的患者与维持剂量组相比,表现出更高的血小板聚集率(59.22±11.67%vs.52.83±12.17%, P<0.001); CYP2C19功能丧失性等位基因携带者与非携带者相比,亦表现出与氯吡格雷预处理策略分组间相似幅度的血小板聚集率升高(59.41±10.91%vs.52.10%±12.90%,P<0.001)。
3.3负荷剂量给药策略在CYP2C19功能丧失性等位基因携带者或非携带者中,均表现出比维持剂量策略更高的血小板聚集率(61.50±10.61%vs.56.84±10.74%,P<0.001；56.06±12.34%vs.46.88±11.78%,P<0.001),且在氯吡格雷给药策略和CYP2C19基因型之间存在对血小板聚集率影响的交互作用(P=0.001)。
3.4在371例接受了冠状动脉支架植入的患者中,分别根据不同的氯吡格雷预处理策略和CYP2C19基因型进行分组,术后的cTNI和CK-MB均未观察到显著的组间差异(P均>0.05)。
4.研究小结
在接受PCI的中国患者中,氯吡格雷300mg负荷剂量组对血小板的抑制作用弱于75mg维持剂量组；该作用差异在CYP2C19功能丧失性等位基因非携带者中更为显著,但对PCI术后的心肌酶学水平无显著影响。
第二部分连续服用氯吡格雷的冠心病患者中单纯冠状动脉造影术与支架植入术对血小板聚集率的影响差异研究
1.研究目的
评价冠状动脉造影检查术或冠状动脉支架植入术两种介入操作对连续服用氯吡格雷的CHD患者血小板聚集率的影响差异。
2.研究方法
2.1研究对象：连续入选2012年5月至2013年5月间在阜外心血管病医院住院,并拟接受PCI治疗的CHD患者,入院前已连续服用氯吡格雷(波利维)75mg/日持续7天以上。
2.2血小板功能检测：分别采集PCI术前及术后12-24小时内的空腹血样本,以ADP(10umol/L)诱导激活的光学比浊法对血小板聚集率进行测定。
2.3根据是否进行冠状动脉支架植入将患者分为冠脉造影组和支架植入组,分别比较两组内术后与术前的血小板聚集率是否存在差异,以及两组间术后与术前的血小板聚集率变化幅度是否存在差异。
2.4在部分患者中探索性研究miR-223与miR-96水平是否与血小板聚集率存在关联。
3.研究结果
3.1总共入选343例接受冠状动脉介入操作的患者,其中单纯冠脉造影组173例,支架植入组170例。
3.2与术前相比,冠脉造影组术后血小板聚集率无明显变化(54.21±11.44%vs.53.15±11.80%,P=0.062)；支架植入组术后血小板聚集率显著升高(55.59±10.47%vs.52.47±11.97%,P<0.001)。
3.3与冠脉造影组相比,支架植入组术后的血小板聚集率升高幅度更为显著(3.12±8.31%vs.1.06±7.40%,P=0.010)。
3.4接受冠脉支架植入的患者中,有66例在术后30天自愿参加了血小板聚集率复测的亚组研究。在该亚组患者中,术后30天的血小板聚集率显著低于术后24小时(54.71±11.64%vs.56.68±10.21%,P=0.019),且与术前基线值相比无显著差异(54.71±11.64%vs.54.26±12.23%,,P=0.901)。
3.5miR-96水平与血小板聚集率存在一定程度关联(相关系数0.380,P=0.038),而miR-223则否(相关系数0.075,P=0.688)。
4.研究小结
冠状动脉支架植入操作会导致术后血小板活性的升高,该作用可在术后30天内消失,而单纯冠状动脉造影则无此影响。
第三部分基于基因型或表现型分组方式对预测氯吡格雷在冠状动脉支架植入术后患者中的临床疗效和安全性效果评价
1.研究目的
评价以CYP2C19基因型或血小板功能表现型两种不同的分组方式,对冠状动脉支架植入术后持续服用氯吡格雷的患者临床预后及安全性的预测价值。
2.研究方法
2.1研究对象：连续入选2012年5月至2013年5月间在阜外心血管病医院住院、接受冠状动脉造影检查并至少植入一枚支架的患者,术后持续给予氯吡格雷75mg/日及阿司匹林100mg/日。
2.2CPY2C19基因测序：采用Taqman(?)技术进行,测量位点包括CYP2C19*2、 CYP2C19*3、CYP2C19*17,根据检测结果将患者按三种不同的代谢型进行分组：超快或快代谢型(*1/*1、*1/*17、*17/*17)、中间代谢型(*1/*2、*1/*3、*2/*17、*3/*17)、慢代谢型(*2/*2、*2/*3、*3*3)。
2.3血小板聚集率检测：以ADP (10umol/L)诱导激活的光学比浊法对血小板聚集率进行测定,根据检测结果将患者按三种不同的表现型进行分组：良好反应者、中度反应者、无反应者。
2.4随访至最后1例入组患者术后6个月,观察主要心脏事件(心脏性死亡、急性心肌梗死、支架内血栓、以及预期外的支架植入血管再次血运重建)、心脏症状事件(上述主要心脏事件以及支架植入术后再次心绞痛发作)、和全部出血事件(GUSTO研究中定义的轻度出血、中度出血、以及致命性出血)的发生率。比较根据基因型或表现型对患者进行分组后,上述事件的发生率是否存在组间差异。
3.研究结果
3.1共入选380例接受了冠状动脉支架植入的患者,其中根据基因型分组,氯吡格雷超快代谢型或快代谢型共157例(41.3%),中间代谢型176例(46.3%),慢代谢型47例(12.4%)；根据表现型分组,氯吡格雷反应良好者98例(25.8%),中度反应者149例(39.2%),无反应者133例(35.0%)。
3.2根据基因型进行分组时,心脏症状事件的发生率在慢代谢型患者中依次高于中间代谢型(34.0%vs.19.1%, HR=2.126,95%CI1.131～3.997, P=0.019)和超快或快代谢型患者(34.0%vs.15.4%, HR=2.772,95%CI1.359～5.655, P=0.005),主要心脏事件和出血事件的发生率无组间显著差异(P均>0.05)
3.3根据表现型进行分组时,出血事件的发生率在反应良好者中依次高于中度反应者(32.7%vs.19.0%, HR=1.919,95%CI1.009～3.650, P=0.047)和无反应者(32.7%vs.18.3%, HR=2.119,95%CI1.045～4.292, P=0.037),主要心脏事件和心脏症状事件的发生率无组间显著差异(P均>0.05)
4.研究小结
氯吡格雷在人群中可以表现为不同的个体反应性,并导致患者的临床预后存在差异。CYP2C19基因型检测结果对冠状动脉支架植入术后心脏缺血性事件的预测更有意义,而血小板功能的表现型检测结果对出血事件的预测更有意义。
三、研究结论
1.300mg负荷剂量的氯吡格雷预处理策略、以及CYP2C19*2或*3LOF等位基因的携带,均是导致氯吡格雷抗血小板作用减弱的因素,且二者之间存在交互关系；这两种因素导致的血小板功能差异,尚不足以影响患者PCI术后的心肌酶学水平；
2.冠状动脉支架植入术会导致血小板活性的一过性升高,在已接受长期抗血小板药物治疗的患者中,介入操作术前的血小板功能检测结果与药物的远期效应更趋于一致；
3. CYP2C19基因型与冠状动脉支架植入术后心脏症状性事件的发生率相关,而血小板功能检测的表现型则与出血风险相关,在未来的研究设计和临床实践中应将两种检测方式结合考虑,用于患者远期预后的预测及抗血小板治疗策略的调整。
Background
Clopidogrel is an inhibitor of P2Y12receptor on the platelet membranin, which blocks its combination with adenosine diphosphate (ADP) to restrain the platelet aggregation. Clopidogrel is administered with aspirin to prevent the recurrent ischemia events in patients suffered from coronary heart disease after percutaneous coronary intervention. It has been demonstrated recently that the dual anti-platelet therapy strategy cannot completely avoid cardiac ischemia events after coronary stent implantation, the residual risk may be related to the insufficient response to the anti-platelet medication, especially because of the individual variability response of clopidogrel.
The metabolic enzyme encoded by CYP2C19plays a pivotal role in active metabolite transformation of clopidogrel through CYP450enzymes in the liver. Patients carried loss-of-function (LOF) allele of CYP2C19do not response well to clopidogrel and may experience a higher risk of stent thrombosis and major adverse cardiovascular events than non-carriers. Results of platelet function test and CYP2C19genotype are considered to be manifestations of individual response to clopidogrel and widely used in clinical trials during anti-platelet therapy strategy decision making. However, none of recent prospective studies showed a positive result when individual anti-platelet strategy was randomly administered in patients with high on-treatment platelet reactivity.
The RDPAC study aimed to evaluate the impact of CYP2C19genotype, clopidogrel pretreatment dose, and PCI procedure to the platelet aggregation, as well as the predict value of long-term clinical outcome by the genotyping of CYP2C19and phenotyping of platelet function, in order to find the evidence based medicine for optimal clopidogrel therapeutic model.
Part1:Impact of clopidogrel pretreatment dose and CYP2C19genotype on platelet aggregation prior to PCI and cardiac enzymes after PCI in patients with coronary heart disease
Objectives
To evaluate the platelet inhibition effect difference between the two clopidogrel
pretreatment strategies:300-mg loading dose (LD) in clopidogrel naive patients or75-mg maintenance dose (MD) in patients received chronic clopidogrel therapy in CHD patients with different CYP2C19genotypes.
Methods
CHD patients administered in Fuwai hospital undergoing elective PCI during May
2012to May2013were assigned to2X2groups according to different clopidogrel pretreatment strategies (470patients in the LD group versus370patients in the MD group) and CYP2C19genotypes (494carriers of any CYP2C19*2or*3LOF allele versus346non-carriers). The primary outcome was platelet aggregation (PA) as measured by the10μmol/L ADP induced light transmission aggregation prior to PCI and cardiac enzymes (cTNl and CK-MB) after PCI between the different groups.
Results
1. Compared with the MD group, the LD strategy showed a significantly higher on-treatment PA (59.22±11.67%vs.52.83±12.17%, P<0.001), similar PA difference was observed in the CYP2C19loss-of-function carriers compared with the non-carriers (59.41110.91%vs.52.10%±12.90%P<0.001).
2. Patients treated with the LD strategy in either the CYP2C19loss-of-function allele carrier or non-carrier group showed a significantly higher PA compared with the MD group (61.50±10.61%vs.56.84±10.74%, P<0.001;56.06±12.34%vs.46.88±11.78%, P<0.001, respectively), a quantitative interaction effect was observed between the clopidogrel pre-treatment strategy and CYP2C19genotype (P=0.001).
3.371patients received coronary stent implantation, both cTNl and CK-MB levels were not significantly different between groups defined by clopidogrel pretreatment strategy or CYP2C19genotype (P>0.05). Part2:Impact of coronary angiography and stent implantation on platelet aggregation in CHD patients under chronic clopidogrel therapy
Objectives To evaluate the impact of coronary angiography and stent implantation procedure
on platelet aggregation in CHD patients under chronic clopidogrel therapy.
Methods CHD patients administered in Fuwai hospital who had been treated with clopidogrel (75mg/day) and aspirin (100mg/day) for at least7consecutive days undergoing elective PCI were prospectively enrolled during May2012to May2013. Based on whether a coronary stent was implanted, all of the included patients were divided into two groups:the coronary angiography (CAG) group and the coronary stent implantation (CSI) group. The differences in PA as measured by the10μmol/L ADP induced light transmission aggregation between the preoperative baseline level and the level at24hours after the procedures in both patient groups were determined.
Results
1. A total of343patients receiving coronary intervention were enrolled in this study, including173patients in the CAG group and170patients in the CSI group.
2. Compared with the preoperative baseline, there was no significant difference in PA after the operation in the CAG group (54.21111.44%vs.53.15±11.80%, P=0.062), while a significant postoperative PA increase was observed in the CSI group (55.59110.47%vs.52.47111.97%, P<0.001).
3. Compared with the CAG group, the PA increase in the CSI group was significantly greater (the mean PA increase was2.07%,95%CI:0.40%to3.74%; P=0.010).
4.66patients received repetitive PA testing30days after coronary stent implantation, which is significantly lower than the PA24hours after PCI (54.71±11.64%vs.56.68±10.21%, P=0.019) and comparable with the baseline PA before procedure (54.71±11.64%vs.54.26±12.23%, P=0.901) in this subgroup.
Part3:Grouping by the phenotype vs. genotype for prediction of clinical efficacy and safety in patients received clopidogrel underwent PCI
Objectives
To evaluate the predictive value of both CYP2C19genotype and platelet function phenotype grouping in clinical outcome and bleeding events of patients received clopidogrel underwent PCI.
Methods
CHD patients administered in Fuwai hospital underwent elective PCI and received coronary stent implantation were prospectively enrolled during October2012to May2013. Patients were assigned into groups by genotype of CYP2C19(extensive metabolizers, intermediate metabolizers, and poor metabolizers) and phenotype of platelet function (clopidogrel responders, semi-responders, and non-responders). The rates of major adverse cardiovascular events, cardiovascular symptom events, and bleeding events were recorded during a follow-up period until6months after the last patient first visit and compared among the groups defined previously.
Results
1.380patients received coronary stent implantation were enrolled in this study, including157(41.3%) clopidogrel extensive metabolizers,176(46.3%) intermediate metabolizers, and47(12.4%) poor metabolizers according to the genotype grouping;98(25.8%) were responders to clopidogrel,149(39.2%) were semi-responders, and133(35.0%) were non-responders according to the phenotype grouping.
2. The highest cardiovascular symptom events rate was observed in the poor metabolizers (34.0%) as compared to the intermediate metabolizers (19.1%, HR=2.126,95%CI1.131～3.997, P=0.019) and the extensive metabolizers (15.4%, HR=2.772,95%CI1.359～5.655, P=0.005) when grouping by the CYP2C19genotype, without a statistical difference of the major adverse cardiovascular events rate or bleeding events rate.
3. The highest bleeding events rate was observed in the clopidogrel responders (32.7%) as compared to the semi-responders (19.0%, HR=1.919,95%CI1.009～3.650, P=0.047) and non-responders (18.3%, HR=2.119,95%CI1.045～4.292, P=0.037) when grouping by the platelet function phenotype, without a statistical difference of the major adverse cardiovascular events rate or cardiovascular symptom events rate.
Conclusions
1. The300-mg LD strategy results in a decreased effect on platelet inhibition compared with the75-mg MD in Chinese patients receiving clopidogrel prior to PCI, interacted with the CYP2C19*2or*3LOF allele carriage. The platelet function difference due to clopidogrel pretreatment strategy cannot affect the cardiac enzyme level after PCI.
2. Coronary stent implantation causes a transient increased ADP-induced PA, while the coronary angiography procedure does not. The result of platelet function test before PCI is in accordance with the effect of long term anti-platelet medication in patients received chronic clopidogrel therapy.
3. Genotyping of CYP2C19is a better predictor of cardiovascular symptom events, while phenotyping of platelet response to clopidogrel is a better predictor of bleeding events in CHD patients received coronary stent implantation. Further study design and clinical practice should take into account both in anti-platelet therapy strategy decision and long term prognosis prediction.
氯吡格雷作为血小板膜蛋白P2Y12受体的抑制剂,通过阻断其与二磷酸腺苷(ADP)的结合发挥抑制血小板聚集作用。该药与阿司匹林联合应用,预防冠状动脉粥样硬化性心脏病(冠心病,CHD)患者接受了经皮冠状动脉介入治疗(PCI)术后的心脏缺血性事件复发,已成为目前美国、欧洲及我国指南共同推荐的常规治疗策略。
近年的研究表明,这种双联抗血小板的治疗策略尚不能完全避免冠状动脉支架植入术后心脏缺血性事件的发生,其剩余风险可能与抗血小板药物的个体反应性,特别是氯吡格雷的个体间差异存在一定程度的关联。
目前已知一种由CYP2C19基因编码的代谢酶,在氯吡格雷经肝脏代谢转化为活性产物的过程中发挥着至关重要的作用。携带该功能丧失性等位基因的患者表现为对氯吡格雷反应性不佳,成为PCI术后支架内血栓形成及主要心血管不良事件发生的一个重要因素。血小板功能检测结果作为抗血小板药物疗效的一种表现形式,与CYP2C19基因型一并成为评价个体对氯吡格雷反应性的指标,在临床研究中作为个体化治疗策略调整的依据被广泛采用。然而,近期数个依据血小板活性对患者进行分组并给予不同治疗方案的前瞻性临床研究却未能取得预期的阳性结果。
本研究拟以血小板聚集率为指标,评价CYP2C19基因型、不同剂量的氯吡格雷预处理策略和PCI介入操作本身对该指标的影响,了解其各自之间的关联性；并以冠状动脉支架植入术后心血管事件和出血事件的发生率为指标,评价根据CYP2C19的基因型或血小板聚集率的表现型两种分组方式对患者远期预后的预测价值,为进一步寻找最佳的氯吡格雷治疗模式提供相应的理论依据。
二、研究内容及结果
第一部分不同氯吡格雷预处理剂量CYP2C19基因型对冠心病患者PCI术前血小板聚集率、术后心肌酶学指标的影响
1.研究目的
评价PCI术前两种不同的氯吡格雷预处理策略：未曾服用该药的患者接受300mg负荷剂量,对比已长期服用该药75mg每日一次的维持剂量,在不同CYP2C19基因型的CHD患者中是否存在血小板抑制作用的差异。
2.研究方法
2.1研究对象：连续入选2012年5月至2013年5月间在阜外心血管病医院住院,并拟接受PCI治疗的CHD患者。入院前已连续服用氯吡格雷(波利维)75mg/日持续7天以上(维持剂量组),或未曾服用过氯吡格雷(负荷剂量组)。
2.2CYP2C19基因型检测：采用Taqman(?)技术在全部患者中进行,测量位点包括CYP2C19*2、CYP2C19*3、CYP2C19*17。除外*17携带者后,依患者是否携带*2或*3任一功能丧失性(LOF)等位基因,将其分为携带者组与非携带者组。2.3血小板功能检测：负荷剂量组患者在服用300mg氯吡格雷后12小时,维持剂量组患者在上一次服用75mg氯吡格雷后24小时进行空腹采血,以ADP (10umol/L)诱导激活的光学比浊法对血小板聚集率进行测定。
2.4依据上述氯吡格雷预处理策略和CYP2C19基因型两种方式对患者进行两两分组,比较在全部患者中PCI术前的血小板聚集率、以及在接受冠状动脉支架植入患者中术后的心肌酶学指标(cTNI和CK-MB)在不同组间是否存在差异。
3.研究结果
3.1在全部入选的840例患者中,根据氯吡格雷的预处理策略(负荷剂量组470例,维持剂量组370例),以及CYP2C19基因型(CYP2C19*2或*3LOF等位基因携带者494例,非携带者346例)进行了两两分组及进一步的2×2分组。
3.2接受负荷剂量的患者与维持剂量组相比,表现出更高的血小板聚集率(59.22±11.67%vs.52.83±12.17%, P<0.001); CYP2C19功能丧失性等位基因携带者与非携带者相比,亦表现出与氯吡格雷预处理策略分组间相似幅度的血小板聚集率升高(59.41±10.91%vs.52.10%±12.90%,P<0.001)。
3.3负荷剂量给药策略在CYP2C19功能丧失性等位基因携带者或非携带者中,均表现出比维持剂量策略更高的血小板聚集率(61.50±10.61%vs.56.84±10.74%,P<0.001；56.06±12.34%vs.46.88±11.78%,P<0.001),且在氯吡格雷给药策略和CYP2C19基因型之间存在对血小板聚集率影响的交互作用(P=0.001)。
3.4在371例接受了冠状动脉支架植入的患者中,分别根据不同的氯吡格雷预处理策略和CYP2C19基因型进行分组,术后的cTNI和CK-MB均未观察到显著的组间差异(P均>0.05)。
4.研究小结
在接受PCI的中国患者中,氯吡格雷300mg负荷剂量组对血小板的抑制作用弱于75mg维持剂量组；该作用差异在CYP2C19功能丧失性等位基因非携带者中更为显著,但对PCI术后的心肌酶学水平无显著影响。
第二部分连续服用氯吡格雷的冠心病患者中单纯冠状动脉造影术与支架植入术对血小板聚集率的影响差异研究
1.研究目的
评价冠状动脉造影检查术或冠状动脉支架植入术两种介入操作对连续服用氯吡格雷的CHD患者血小板聚集率的影响差异。
2.研究方法
2.1研究对象：连续入选2012年5月至2013年5月间在阜外心血管病医院住院,并拟接受PCI治疗的CHD患者,入院前已连续服用氯吡格雷(波利维)75mg/日持续7天以上。
2.2血小板功能检测：分别采集PCI术前及术后12-24小时内的空腹血样本,以ADP(10umol/L)诱导激活的光学比浊法对血小板聚集率进行测定。
2.3根据是否进行冠状动脉支架植入将患者分为冠脉造影组和支架植入组,分别比较两组内术后与术前的血小板聚集率是否存在差异,以及两组间术后与术前的血小板聚集率变化幅度是否存在差异。
2.4在部分患者中探索性研究miR-223与miR-96水平是否与血小板聚集率存在关联。
3.研究结果
3.1总共入选343例接受冠状动脉介入操作的患者,其中单纯冠脉造影组173例,支架植入组170例。
3.2与术前相比,冠脉造影组术后血小板聚集率无明显变化(54.21±11.44%vs.53.15±11.80%,P=0.062)；支架植入组术后血小板聚集率显著升高(55.59±10.47%vs.52.47±11.97%,P<0.001)。
3.3与冠脉造影组相比,支架植入组术后的血小板聚集率升高幅度更为显著(3.12±8.31%vs.1.06±7.40%,P=0.010)。
3.4接受冠脉支架植入的患者中,有66例在术后30天自愿参加了血小板聚集率复测的亚组研究。在该亚组患者中,术后30天的血小板聚集率显著低于术后24小时(54.71±11.64%vs.56.68±10.21%,P=0.019),且与术前基线值相比无显著差异(54.71±11.64%vs.54.26±12.23%,,P=0.901)。
3.5miR-96水平与血小板聚集率存在一定程度关联(相关系数0.380,P=0.038),而miR-223则否(相关系数0.075,P=0.688)。
4.研究小结
冠状动脉支架植入操作会导致术后血小板活性的升高,该作用可在术后30天内消失,而单纯冠状动脉造影则无此影响。
第三部分基于基因型或表现型分组方式对预测氯吡格雷在冠状动脉支架植入术后患者中的临床疗效和安全性效果评价
1.研究目的
评价以CYP2C19基因型或血小板功能表现型两种不同的分组方式,对冠状动脉支架植入术后持续服用氯吡格雷的患者临床预后及安全性的预测价值。
2.研究方法
2.1研究对象：连续入选2012年5月至2013年5月间在阜外心血管病医院住院、接受冠状动脉造影检查并至少植入一枚支架的患者,术后持续给予氯吡格雷75mg/日及阿司匹林100mg/日。
2.2CPY2C19基因测序：采用Taqman(?)技术进行,测量位点包括CYP2C19*2、 CYP2C19*3、CYP2C19*17,根据检测结果将患者按三种不同的代谢型进行分组：超快或快代谢型(*1/*1、*1/*17、*17/*17)、中间代谢型(*1/*2、*1/*3、*2/*17、*3/*17)、慢代谢型(*2/*2、*2/*3、*3*3)。
2.3血小板聚集率检测：以ADP (10umol/L)诱导激活的光学比浊法对血小板聚集率进行测定,根据检测结果将患者按三种不同的表现型进行分组：良好反应者、中度反应者、无反应者。
2.4随访至最后1例入组患者术后6个月,观察主要心脏事件(心脏性死亡、急性心肌梗死、支架内血栓、以及预期外的支架植入血管再次血运重建)、心脏症状事件(上述主要心脏事件以及支架植入术后再次心绞痛发作)、和全部出血事件(GUSTO研究中定义的轻度出血、中度出血、以及致命性出血)的发生率。比较根据基因型或表现型对患者进行分组后,上述事件的发生率是否存在组间差异。
3.研究结果
3.1共入选380例接受了冠状动脉支架植入的患者,其中根据基因型分组,氯吡格雷超快代谢型或快代谢型共157例(41.3%),中间代谢型176例(46.3%),慢代谢型47例(12.4%)；根据表现型分组,氯吡格雷反应良好者98例(25.8%),中度反应者149例(39.2%),无反应者133例(35.0%)。
3.2根据基因型进行分组时,心脏症状事件的发生率在慢代谢型患者中依次高于中间代谢型(34.0%vs.19.1%, HR=2.126,95%CI1.131～3.997, P=0.019)和超快或快代谢型患者(34.0%vs.15.4%, HR=2.772,95%CI1.359～5.655, P=0.005),主要心脏事件和出血事件的发生率无组间显著差异(P均>0.05)
3.3根据表现型进行分组时,出血事件的发生率在反应良好者中依次高于中度反应者(32.7%vs.19.0%, HR=1.919,95%CI1.009～3.650, P=0.047)和无反应者(32.7%vs.18.3%, HR=2.119,95%CI1.045～4.292, P=0.037),主要心脏事件和心脏症状事件的发生率无组间显著差异(P均>0.05)
4.研究小结
氯吡格雷在人群中可以表现为不同的个体反应性,并导致患者的临床预后存在差异。CYP2C19基因型检测结果对冠状动脉支架植入术后心脏缺血性事件的预测更有意义,而血小板功能的表现型检测结果对出血事件的预测更有意义。
三、研究结论
1.300mg负荷剂量的氯吡格雷预处理策略、以及CYP2C19*2或*3LOF等位基因的携带,均是导致氯吡格雷抗血小板作用减弱的因素,且二者之间存在交互关系；这两种因素导致的血小板功能差异,尚不足以影响患者PCI术后的心肌酶学水平；
2.冠状动脉支架植入术会导致血小板活性的一过性升高,在已接受长期抗血小板药物治疗的患者中,介入操作术前的血小板功能检测结果与药物的远期效应更趋于一致；
3. CYP2C19基因型与冠状动脉支架植入术后心脏症状性事件的发生率相关,而血小板功能检测的表现型则与出血风险相关,在未来的研究设计和临床实践中应将两种检测方式结合考虑,用于患者远期预后的预测及抗血小板治疗策略的调整。
Background
Clopidogrel is an inhibitor of P2Y12receptor on the platelet membranin, which blocks its combination with adenosine diphosphate (ADP) to restrain the platelet aggregation. Clopidogrel is administered with aspirin to prevent the recurrent ischemia events in patients suffered from coronary heart disease after percutaneous coronary intervention. It has been demonstrated recently that the dual anti-platelet therapy strategy cannot completely avoid cardiac ischemia events after coronary stent implantation, the residual risk may be related to the insufficient response to the anti-platelet medication, especially because of the individual variability response of clopidogrel.
The metabolic enzyme encoded by CYP2C19plays a pivotal role in active metabolite transformation of clopidogrel through CYP450enzymes in the liver. Patients carried loss-of-function (LOF) allele of CYP2C19do not response well to clopidogrel and may experience a higher risk of stent thrombosis and major adverse cardiovascular events than non-carriers. Results of platelet function test and CYP2C19genotype are considered to be manifestations of individual response to clopidogrel and widely used in clinical trials during anti-platelet therapy strategy decision making. However, none of recent prospective studies showed a positive result when individual anti-platelet strategy was randomly administered in patients with high on-treatment platelet reactivity.
The RDPAC study aimed to evaluate the impact of CYP2C19genotype, clopidogrel pretreatment dose, and PCI procedure to the platelet aggregation, as well as the predict value of long-term clinical outcome by the genotyping of CYP2C19and phenotyping of platelet function, in order to find the evidence based medicine for optimal clopidogrel therapeutic model.
Part1:Impact of clopidogrel pretreatment dose and CYP2C19genotype on platelet aggregation prior to PCI and cardiac enzymes after PCI in patients with coronary heart disease
Objectives
To evaluate the platelet inhibition effect difference between the two clopidogrel
pretreatment strategies:300-mg loading dose (LD) in clopidogrel naive patients or75-mg maintenance dose (MD) in patients received chronic clopidogrel therapy in CHD patients with different CYP2C19genotypes.
Methods
CHD patients administered in Fuwai hospital undergoing elective PCI during May
2012to May2013were assigned to2X2groups according to different clopidogrel pretreatment strategies (470patients in the LD group versus370patients in the MD group) and CYP2C19genotypes (494carriers of any CYP2C19*2or*3LOF allele versus346non-carriers). The primary outcome was platelet aggregation (PA) as measured by the10μmol/L ADP induced light transmission aggregation prior to PCI and cardiac enzymes (cTNl and CK-MB) after PCI between the different groups.
Results
1. Compared with the MD group, the LD strategy showed a significantly higher on-treatment PA (59.22±11.67%vs.52.83±12.17%, P<0.001), similar PA difference was observed in the CYP2C19loss-of-function carriers compared with the non-carriers (59.41110.91%vs.52.10%±12.90%P<0.001).
2. Patients treated with the LD strategy in either the CYP2C19loss-of-function allele carrier or non-carrier group showed a significantly higher PA compared with the MD group (61.50±10.61%vs.56.84±10.74%, P<0.001;56.06±12.34%vs.46.88±11.78%, P<0.001, respectively), a quantitative interaction effect was observed between the clopidogrel pre-treatment strategy and CYP2C19genotype (P=0.001).
3.371patients received coronary stent implantation, both cTNl and CK-MB levels were not significantly different between groups defined by clopidogrel pretreatment strategy or CYP2C19genotype (P>0.05). Part2:Impact of coronary angiography and stent implantation on platelet aggregation in CHD patients under chronic clopidogrel therapy
Objectives To evaluate the impact of coronary angiography and stent implantation procedure
on platelet aggregation in CHD patients under chronic clopidogrel therapy.
Methods CHD patients administered in Fuwai hospital who had been treated with clopidogrel (75mg/day) and aspirin (100mg/day) for at least7consecutive days undergoing elective PCI were prospectively enrolled during May2012to May2013. Based on whether a coronary stent was implanted, all of the included patients were divided into two groups:the coronary angiography (CAG) group and the coronary stent implantation (CSI) group. The differences in PA as measured by the10μmol/L ADP induced light transmission aggregation between the preoperative baseline level and the level at24hours after the procedures in both patient groups were determined.
Results
1. A total of343patients receiving coronary intervention were enrolled in this study, including173patients in the CAG group and170patients in the CSI group.
2. Compared with the preoperative baseline, there was no significant difference in PA after the operation in the CAG group (54.21111.44%vs.53.15±11.80%, P=0.062), while a significant postoperative PA increase was observed in the CSI group (55.59110.47%vs.52.47111.97%, P<0.001).
3. Compared with the CAG group, the PA increase in the CSI group was significantly greater (the mean PA increase was2.07%,95%CI:0.40%to3.74%; P=0.010).
4.66patients received repetitive PA testing30days after coronary stent implantation, which is significantly lower than the PA24hours after PCI (54.71±11.64%vs.56.68±10.21%, P=0.019) and comparable with the baseline PA before procedure (54.71±11.64%vs.54.26±12.23%, P=0.901) in this subgroup.
Part3:Grouping by the phenotype vs. genotype for prediction of clinical efficacy and safety in patients received clopidogrel underwent PCI
Objectives
To evaluate the predictive value of both CYP2C19genotype and platelet function phenotype grouping in clinical outcome and bleeding events of patients received clopidogrel underwent PCI.
Methods
CHD patients administered in Fuwai hospital underwent elective PCI and received coronary stent implantation were prospectively enrolled during October2012to May2013. Patients were assigned into groups by genotype of CYP2C19(extensive metabolizers, intermediate metabolizers, and poor metabolizers) and phenotype of platelet function (clopidogrel responders, semi-responders, and non-responders). The rates of major adverse cardiovascular events, cardiovascular symptom events, and bleeding events were recorded during a follow-up period until6months after the last patient first visit and compared among the groups defined previously.
Results
1.380patients received coronary stent implantation were enrolled in this study, including157(41.3%) clopidogrel extensive metabolizers,176(46.3%) intermediate metabolizers, and47(12.4%) poor metabolizers according to the genotype grouping;98(25.8%) were responders to clopidogrel,149(39.2%) were semi-responders, and133(35.0%) were non-responders according to the phenotype grouping.
2. The highest cardiovascular symptom events rate was observed in the poor metabolizers (34.0%) as compared to the intermediate metabolizers (19.1%, HR=2.126,95%CI1.131～3.997, P=0.019) and the extensive metabolizers (15.4%, HR=2.772,95%CI1.359～5.655, P=0.005) when grouping by the CYP2C19genotype, without a statistical difference of the major adverse cardiovascular events rate or bleeding events rate.
3. The highest bleeding events rate was observed in the clopidogrel responders (32.7%) as compared to the semi-responders (19.0%, HR=1.919,95%CI1.009～3.650, P=0.047) and non-responders (18.3%, HR=2.119,95%CI1.045～4.292, P=0.037) when grouping by the platelet function phenotype, without a statistical difference of the major adverse cardiovascular events rate or cardiovascular symptom events rate.
Conclusions
1. The300-mg LD strategy results in a decreased effect on platelet inhibition compared with the75-mg MD in Chinese patients receiving clopidogrel prior to PCI, interacted with the CYP2C19*2or*3LOF allele carriage. The platelet function difference due to clopidogrel pretreatment strategy cannot affect the cardiac enzyme level after PCI.
2. Coronary stent implantation causes a transient increased ADP-induced PA, while the coronary angiography procedure does not. The result of platelet function test before PCI is in accordance with the effect of long term anti-platelet medication in patients received chronic clopidogrel therapy.
3. Genotyping of CYP2C19is a better predictor of cardiovascular symptom events, while phenotyping of platelet response to clopidogrel is a better predictor of bleeding events in CHD patients received coronary stent implantation. Further study design and clinical practice should take into account both in anti-platelet therapy strategy decision and long term prognosis prediction.
引文
1. Levine GN, Bates ER, Blankenship JC, et al.2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions[J]. Circulation.2011 Dec 6;124(23):e574-651.
2. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators[J]. N Engl J Med.1994 Aug 25;331(8):496-501.
3. Serruys PW1, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group[J]. N Engl J Med.1994 Aug 25;331(8):489-95.
4. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents:a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians[J]. J Am Coll Cardiol.2007 Feb 13;49(6):734-9.
5. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA.2007 Jan 10;297(2):159-68.
6. Savi P, Herbert JM. Clopidogrel and ticlopidine:P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis[J]. Semin Thromb Hemost.2005 Apr;31(2):174-83.
7. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee[J]. Lancet.1996 Nov 16;348(9038):1329-39.
8. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J]. N Engl J Med.2001 Aug 16;345(7):494-502.
9. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel:relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes[J]. Circulation.2009 May 19;119(19):2553-60.
10. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel[J]. N Engl J Med.2009 Jan 22;360(4):354-62.
11. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention[J]. Eur Heart J.2009 Apr;30(8):916-22.
12. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI:a meta-analysis[J]. JAMA.2010 Oct 27;304(16):1821-30.
13. FDA Drug Safety Communication:reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug[EB/OL]. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatients and Providers/ucm203888.htm. Accessed April 28,2010.
14. Plavix (clopidogrel) Label[EB/OL]. Available at:http://www.accessdata.fda.gov/drug satfda_docs/label/2011/020839s055IbI.pdf. Accessed December,2011.
15. Cattaneo M, Hayward CP, Moffat KA, et al. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry:a report from the platelet physiology subcommittee of the SSC of the ISTH[J]. J Thromb Haemost. 2009 Jun;7(6):1029.
16. Jakubowski JA, Payne CD, Li YG, et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry[J]. Thromb Haemost.2008 Jan;99(1):215-22.
17. Malinin A, Pokov A, Swaim L, et al. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel [J]. Methods Find Exp Clin Pharmacol. 2006 Jun;28(5):315-22.
18. Siller-Matula JM, Delle-Karth G, Lang IM, et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety:the PEGASUS-PCI study[J]. J Thromb Haemost.2012 Apr;10(4):529-42.
19. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J]. JAMA.2009 Aug 26;302(8):849-57.
20. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention:the GRAVITAS randomized trial[J]. JAMA.2011 Mar 16;305(11):1097-105.
21. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting[J]. N Engl J Med.2012 Nov 29;367(22):2100-9.
22. Patrono C. Aspirin as an antiplatelet drug[J]. N Engl J Med.1994 May 5;330(18):1287-94.
23. Jennings LK. Mechanisms of platelet activation:need for new strategies to protect against platelet-mediated atherothrombosis[J], Thromb Haemost.2009 Aug;102(2):248-57.
24. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease[J]. Nat Rev Drug Discov.2010 Feb;9(2):154-69.
25. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary:a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions[J]. Circulation.2001 Jun 19;103(24):3019-41.
26. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology[J]. Eur Heart J.2005 Apr;26(8):804-47.
27.中华医学会心血管病学分会,中华心血管病杂志编辑委员会.经皮冠状动脉介入治疗指南[J].中华心血管病杂志.2002；30(12)：707-718.
28. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-,600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial[J]. Circulation.2005 Nov 8;112(19):2946-50.
29. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes:the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial[J]. J Am Coll Cardiol.2006 Sep 5;48(5):931-8.
30. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7):a randomised factorial trial[J]. Lancet.2010 Oct 9;376(9748):1233-43.
31. Wright RS, Anderson JL, Adams CD, et al.2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons[J]. J Am Coll Cardiol.2011 May 10;57(19):e215-367.
32. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) [J]. Eur Heart J.2011 Dec;32(23):2999-3054.
33.中华医学会心血管病学分会,中华心血管病杂志编辑委员会.经皮冠状动脉介入治疗指南(2009)[J].中华心血管病杂志.2009；37(1)：4-25.
34. Collet JP, Montalescot G. et al. Platelet function testing and implications for clinical practice. J Cardiovasc Pharmacol Ther[J].2009 Sep;14(3):157-69.
35. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial[J]. JAMA.2002 Nov 20;288(19):2411-20.
36. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention) [J]. Circulation.2006 Feb 21;113(7):e166-286.
37.中华医学会心血管病学分会介入心脏病学组,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南2012(简本)[J].中华心血管病杂志.2012；40(4)：271-277.
38. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting:response variability, drug resistance, and the effect of pretreatment platelet reactivity [J]. Circulation.2003 Jun 17;107(23):2908-13.
39. Siller-Matula JM, Haberl K, Prillinger K, et al. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation [J]. Thromb Res. 2009 Apr;123(6):874-80.
40. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J]. Drug Metab Dispos.2010 Jan;38(1):92-9.
41. Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy:2013 update[J]. Clin Pharmacol Ther.2013 Sep;94(3):317-23.
42. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J]. Circulation.2010 Feb 2;121(4):512-8.
43. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J]. JAMA.2009 Aug 26;302(8):849-57.
44. Tantry US, Bliden KP, Wei C, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel:the ONSET/OFFSET and RESPOND genotype studies[J]. Circ Cardiovasc Genet.2010 Dec;3(6):556-66.
45. Frere C, Cuisset T, Gaborit B, et al. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome[J]. J Thromb Haemost.2009 Aug;7(8):1409-11.
46. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation[J]. N Engl J Med.2008 Mar 6;358(10):999-1008.
47. Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention:is the current antiplatelet therapy adequate[J]? J Am Coll Cardiol.2007 Feb 13;49(6):657-66.
48.中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高急性冠状动脉综合征诊断和治疗指南[J].中华心血管病杂志.2012；40(5)：353-67.
49. Ellis SG, Chew D, Chan A, et al. Death following creatine kinase-MB elevation after coronary intervention:identification of an early risk period:importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy[J]. Circulation.2002 Sep 3;106(10):1205-10.
50. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation [J]. JAMA.2010 Feb 24;303(8):754-62.
51. Collet JP, Silvain J, Landivier A, et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose:the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study[J]. Circulation.2008 Sep 16;118(12):1225-33.
52. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med.2007 Nov 15;357(20):2001-15.
53. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med.2009 Sep 10;361(11):1045-57.
54. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals[J]. J Am Coll Cardiol.2005 Jan 18;45(2):246-51.
55. Sofi F, Marcucci R, Gori AM, et al. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis[J]. Thromb Haemost.2010 Apr;103(4):841-8.
56. Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting[J]. J Am Coll Cardiol.2005 May 3;45(9):1392-6.
57. Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis[J]. Am J Cardiol.2009 Jan 1;103(1):5-10.
58. Gurbel PA, Samara WM, Bliden KP. et al. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting:implications for thrombotic events and restenosis[J]. Platelets.2004 Mar;15(2):95-9.
59. Gawaz M, Neumann FJ, Ott I, et al. Changes in membrane glycoproteins of circulating platelets after coronary stent implantation[J]. Heart.1996 Aug;76(2):166-72.
60. Jaster M, Schwimmbeck P, Spencker S, et al. Randomized comparison of platelet-leukocyte aggregates and platelet activation in blood:heparin-coated coiled wire stent implantation versus balloon angioplasty in acute myocardial infarction [J]. Thromb Res.2003;112(5-6):285-9.
61. Bonello L, Harhouri K, Sabatier F, et al. Level of adenosine diphosphate receptor P2Y12 blockade during percutaneous coronary intervention predicts the extent of endothelial injury, assessed by circulating endothelial cell measurement[J]. J Am Coll Cardiol.2010 Sep 21;56(13):1024-31.
62. Siller-Matula JM, Haberl K, Prillinger K, et al. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation[J]. Thromb Res. 2009 Apr;123(6):874-80.
63. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers[J]. PLoS One.2008 Sep 5;3(9):e3148.
64.桂俊豪,田亚平,温新宇等.临床血清循环miRNAs定量技术的建立[J].军医进修学院学报2010 Apr；31(4)：363-6.
65. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma[J]. Br J Haematol.2008 May;141(5):672-5.
66. Landry P, Plante I, Ouellet DL, et al. Existence of a microRNA pathway in anucleate platelets[J]. Nat Struct Mol Biol.2009 Sep;16(9):961-6.
67. Kondkar AA, Bray MS, Leal SM, et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets:suggested role for platelet microRNA[J]. J Thromb Haemost.2010 Feb;8(2):369-78.
68. Shi R, Ge L, Zhou X, et al. Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity [J]. Thromb Res.2013 Jun;131(6):508-13.
69. Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES):a prospective multicentre registry study[J]. Lancet.2013 Aug 17;382(9892):614-23.
70. Price MJ, Coleman JL, Steinhubl SR, et al. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers[J]. Am J Cardiol.2006 Sep 1;98(5):681-4.
71. Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement[J]. J Am Coll Cardiol.2010 Jun 1;55(22):2427-34.
72. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate[J]. J Am Coll Cardiol.2010 Sep 14;56(12):919-33.
73. Siller-Matula JM, Christ G, Lang IM, et al. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay[J]. J Thromb Haemost.2010 Feb;8(2):351-9.
74. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis[J]. J Am Coll Cardiol.2009 Mar 10;53(10):849-56.
75. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med.2009 Jan 22;360(4):363-75.
76. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators[J]. N Engl J Med.1993 Sep 2;329(10):673-82.
77. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects[J]. Blood.2006 Oct 1;108(7):2244-7.
78. Li Y, Tang HL, Hu YF, et al. The gain-of-function variant allele CYP2C19*17:a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients[J]. J Thromb Haemost.2012 Feb;10(2):199-206.
79. Ahmad T, Voora D, Becker RC. The pharmacogenetics of antiplatelet agents:towards personalized therapy[J]? Nat Rev Cardiol.2011 Aug 9;8(10):560-71.
80. Sibbing D, Gebhard D, Koch W, et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy[J]. J Thromb Haemost.2010 Aug;8(8):1685-93.
81. Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment[J]. N Engl J Med.2010 Oct 28;363(18):1704-14.
82. Gurbel PA1, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease[J]. J Am Coll Cardiol.2007 Nov 6;50(19):1822-34.
83. Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets:results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study[J]. Circulation.2005 Mar 8；111(9):1153-9.
84. Mega JL, Hochholzer W, Frelinger AL 3rd, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA.2011 Nov 23;306(20):2221-8.
85. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity:results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study[J]. J Am Coll Cardiol.2009 Mar 31;53(13):1101-9.
86. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes:a genetic substudy of the PLATO trial[J]. Lancet.2010 Oct 16;376(9749):1320-8.
87. Xie X, Ma YT, Yang YN, et al. Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention:a randomized control trial[J]. Int J Cardiol.2013 Oct 9;168(4):3736-40.
88. Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement[J]. Thromb Haemost.2003 May;89(5):783-7.
89. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement[J]. J Am Coll Cardiol.2006 Nov 7;48(9):1742-50.
90. Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention:is the current antiplatelet therapy adequate[J]? J Am Coll Cardiol.2007 Feb 13;49(6):657-66.
1. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents[J]. N Engl J Med.1996 Apr 25;334(17):1084-9.
2. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting:the clopidogrel aspirin stent international cooperative study (CLASSICS) [J]. Circulation.2000 Aug 8;102(6):624-9.
3. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation[J]. N Engl J Med.2005 Mar 24;352(12):1179-89.
4. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J]. N Engl J Med.2001 Aug 16;345(7):494-502.
5. Levine GN, Bates ER, Blankenship JC, et al.2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions[J]. Circulation.2011 Dec 6;124(23):e574-651.
6. Bonello L1, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate[J]. J Am Coll Cardiol.2010 Sep 14;56(12):919-33.
7. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement[J]. J Am Coll Cardiol.2006 Nov 7;48(9):1742-50.
8. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents[J]. J Am Coll Cardiol.2008 May 20;51(20):1925-34.
9. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis[J]. J Am Coll Cardiol.2009 Mar 10;53(10):849-56.
10. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J]. Circulation.2010 Feb 2;121(4):512-8.
11. Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement[J]. J Am Coll Cardiol.2010 Jun 1;55(22):2427-34.
12. Wallentin L. P2Y(12) inhibitors:differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J.2009 Aug;30(16):1964-77.
13. Ding Z, Kim S, Dorsam RT, et al. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270[J]. Blood.2003 May 15;101(10):3908-14.
14. Gachet C. Regulation of platelet functions by P2 receptors [J]. Annu Rev Pharmacol Toxicol.2006;46:277-300.
15. Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway[J]. Pharmacogenet Genomics. 2010 Jul;20(7):463-5.
16. Gremmel T, Steiner S, Seidinger D, et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation[J]. Thromb Haemost.2009 Feb;101(2):333-9.
17. Gremmel T, Steiner S, Seidinger D, et al. Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation[J]. Platelets.2011;22(3):188-95.
18. Paniccia R1, Antonucci E, Gori AM, et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients[J]. J Thromb Haemost.2007 Sep;5(9):1839-47.
19. von Beckerath N, Sibbing D, Jawansky S, et al. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry[J]. Blood Coagul Fibrinolysis.2010 Jan;21(1):46-52.
20. Cattaneo M, Hayward CP, Moffat KA, et al. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry:a report from the platelet physiology subcommittee of the SSC of the ISTH[J]. J Thromb Haemost. 2009 Jun;7(6):1029.
21. Jakubowski JA, Payne CD, Li YG, et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry[J]. Thromb Haemost.2008 Jan;99(1):215-22.
22. Judge HM, Buckland RJ, Sugidachi A, et al. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function[J]. Thromb Haemost.2010 Jun;103(6):1210-7.
23. Malinin A, Pokov A, Swaim L, et al. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel[J]. Methods Find Exp Clin Pharmacol. 2006 Jun;28(5):315-22.
24. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate[J]. J Am Coll Cardiol.2010 Sep 14;56(12):919-33.
25.Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption[J]. Clin Pharmacol Ther.2006 Nov;80(5):486-501.
26. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med.2009 Jan 22;360(4):363-75.
27. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial:a pharmacogenetic analysis[J]. Lancet.2010 Oct 16;376(9749):1312-9.
28. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes:a genetic substudy of the PLATO trial[J]. Lancet.2010 Oct 16;376(9749):1320-8.
29. Luo M, Li J, Xu X, et al. ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients:a meta-analysis[J]. Thromb Res.2012 Jun;129(6):754-9.
30. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J]. Drug Metab Dispos.2010 Jan;38(1):92-9.
31. Steinhubl SR. Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines[J]. Circulation.2010 Feb 2;121(4):481-3.
32. Kubica A, Kozinski M, Grzesk G, et al. Genetic determinants of platelet response to clopidogrel[J]. J Thromb Thrombolysis.2011 Nov;32(4):459-66.
33. Smock KJ, Saunders PJ, Rodgers GM, et al. Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods[J]. Am J Hematol.2011 Dec;86(12):1032-4.
34. Ahmad T, Voora D, Becker RC. The pharmacogenetics of antiplatelet agents:towards personalized therapypy[J]? Nat Rev Cardiol.2011 Aug 9;8(10):560-71.
35. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI:a meta-analysis[J]. JAMA.2010 Oct 27;304(16):1821-30.
36. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J]. Circulation.2010 Feb 2;121(4):512-8.
37. Li Y, Tang HL, Hu YF, et al. The gain-of-function variant allele CYP2C19*17:a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients[J]. J Thromb Haemost.2012 Feb;10(2):199-206.
38. Plavix [package insert] [EB/OL]. Bridgewater, NJ:Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; 2011.
39. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention[J]. Eur Heart J.2009 Apr;30(8):916-22.
40. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel[J]. N Engl J Med.2009 Jan 22;360(4):354-62.
41. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration:a systematic meta-analysis[J]. J Am Coll Cardiol.2010 Jul 6;56(2):134-43.
42. Bouman HJ, Schomig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy[J]. Nat Med.2011 Jan;17(1):110-6.
43. Fontana P, James R, Barazer I, et al. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study[J]. J Thromb Haemost.2011 Aug;9(8):1664-6.
44. Lewis JP, Fisch AS, Ryan K, et al. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response[J]. Clin Pharmacol Ther.2011 Oct;90(4):568-74.
45. Sibbing D, Koch W, Massberg S, et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting[J]. Eur Heart J.2011 Jul;32(13):1605-13.
46. Shuldiner AR1, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J]. JAMA.2009 Aug 26;302(8):849-57.
47. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease [J]. Thromb Res.2005;116(6):491-7.
48. Ishizaki T, Horai Y. Review article:cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole[J]. Aliment Pharmacol Ther.1999 Aug;13 Suppl 3:27-36.
49. Horn J. Review article:relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole[J]. Aliment Pharmacol Ther.2004 Nov;20 Suppl 6:11-9.
50. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin:the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study[J]. J Am Coll Cardiol.2008 Jan 22;51(3):256-60.
51. Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study[J]. J Am Coll Cardiol.2009 Sep 22;54(13):1149-53.
52. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel [J]. Am Heart J.2009 Jan;157(1):148.e1-5.
53. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med.2009 Jan 22;360(4):363-75.
54. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors:a cohort study[J]. Ann Intern Med.2010 Mar 16;152(6):337-45.
55. Kwok CS, Loke YK. Meta-analysis:the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel [J]. Aliment Pharmacol Ther.2010 Apr;31(8):810-23.
56. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease[J]. N Engl J Med.2010 Nov 11;363(20):1909-17.
57. Levine GN, Bates ER, Blankenship JC, et al.2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions[J]. Circulation.2011 Dec 6;124(23):e574-651.
58. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase[J]. Science.2001 May 11;292(5519):1160-4.
59. Bellosta S1, Paoletti R, Corsini A. Safety of statins:focus on clinical pharmacokinetics and drug interactions[J]. Circulation.2004 Jun 15;109(23 Suppl 1):III50-7.
60. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin[J]. Drug Metab Dispos.2003 Jan;31(1):53-9.
61. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation:a new drug-drug interaction[J]. Circulation.2003 Jan 7;107(1):32-7.
62. Muller I, Besta F, Schulz C, et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel[J]. Circulation.2003 Nov 4;108(18):2195-7.
63. Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial[J]. Circulation.2003 Aug 26;108(8):921-4.
64. Lim MJ, Spencer FA, Gore JM, et al. Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes:perspectives from a large multinational registry[J]. Eur Heart J.2005 Jun;26(11):1063-9.
65. Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies[J]. Am J Cardiol.2003 Aug 1;92(3):285-8.
66. Saw J, Brennan DM, Steinhubl SR, et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial[J]. J Am Coll Cardiol.2007 Jul 24;50(4):291-5.
67. Siller-Matula JM, Lang I, Christ G, et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel[J]. J Am Coll Cardiol.2008 Nov 4;52(19):1557-63.
68. Olesen JB, Gislason GH, Chariot MG, et al. Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction:a nationwide cohort study[J]. J Am Coll Cardiol.2011 Jan 25;57(4):409-17.
69. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J]. Circulation.2010 Feb 2;121(4):512-8.
70. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med.2009 Jan 22;360(4):363-75.
71. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment[J]. Diabetes.2005 Aug;54(8):2430-5.
72. Angiolillo DJ, Bernardo E, Ramirez C, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment[J]. J Am Coll Cardiol.2006 Jul 18;48(2):298-304.
73. Ferroni P, Basili S, Falco A, et al. Platelet activation in type 2 diabetes mellitus[J]. J Thromb Haemost.2004 Aug;2(8):1282-91.
74. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance:an emerging clinical entity[J]. Eur Heart J.2006 Mar;27(6):647-54.
75. Gawaz M, Neumann FJ, Ott I, et al. Platelet function in acute myocardial infarction treated with direct angioplasty[J]. Circulation.1996 Jan 15;93(2):229-37.
76. Serebruany VL, Malinin Al, Jerome SD, et al. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure:the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial[J]. Am Heart J.2003 Oct; 146(4):713-20.
77. Soffer D, Moussa I, Harjai KJ, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention:do we need more aggressive dosing regimens in unstable angina[J]? Catheter Cardiovasc Interv.2003 May;59(1):21-5.
78. Siller-Matula JM, Haberl K, Prillinger K, et al. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation[J]. Thromb Res. 2009 Apr;123(6):874-80.
79. CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes[J]. N Engl J Med.2010 Sep 2;363(10):930-42.
80. Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI[J]. JAMA.2011 Sep 21;306(11):1215-23.
81. Price MJ, Berger PB, Teirstein PS, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention:the GRAVITAS randomized trial[J]. JAMA.2011 Mar 16;305(11):1097-105.
82. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting[J]. N Engl J Med.2012 Nov 29;367(22):2100-9.
83. FDA Drug Safety Communication:reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug[EB/OL]. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatients and Providers/ucm203888.htm. Accessed April 28,2010.
84. GIANT ongoing trial-US National Library of Medicine[EB/OL]. ClinicalTrials.gov. http://clinicaltrial.gov/ct2/show/NCT01134380(2010) Accessed November 10,2011.
85. GeCCo ongoing trial-US National Library of Medicine[EB/OL]. ClinicalTrials.gov. http://clinicaltrial.gov/ct2/show/NCT00995514(2009). Accessed November 10, 2011.
86. RAPID-STEMI ongoing trial-US National Library of Medicine[EB/OL]. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT01452139(2011) Accessed January 3,2012.
87. Mega JL, Hochholzer WFrelinger AL 3rd, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease[J]. JAMA.2011 Nov 23;306(20):2221-8.
88. Michelson AD, Frelinger AL 3rd, Braunwald E, et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial[J]. Eur Heart J.2009 Jul;30(14):1753-63.
89. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med.2007 Nov 15;357(20):2001-15.
90. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med.2009 Sep 10;361(11):1045-57.
2. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators[J]. N Engl J Med.1994 Aug 25;331(8):496-501.
3. Serruys PW1, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group[J]. N Engl J Med.1994 Aug 25;331(8):489-95.
4. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents:a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians[J]. J Am Coll Cardiol.2007 Feb 13;49(6):734-9.
5. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA.2007 Jan 10;297(2):159-68.
6. Savi P, Herbert JM. Clopidogrel and ticlopidine:P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis[J]. Semin Thromb Hemost.2005 Apr;31(2):174-83.
7. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee[J]. Lancet.1996 Nov 16;348(9038):1329-39.
8. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J]. N Engl J Med.2001 Aug 16;345(7):494-502.
9. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel:relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes[J]. Circulation.2009 May 19;119(19):2553-60.
10. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel[J]. N Engl J Med.2009 Jan 22;360(4):354-62.
11. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention[J]. Eur Heart J.2009 Apr;30(8):916-22.
12. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI:a meta-analysis[J]. JAMA.2010 Oct 27;304(16):1821-30.
13. FDA Drug Safety Communication:reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug[EB/OL]. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatients and Providers/ucm203888.htm. Accessed April 28,2010.
14. Plavix (clopidogrel) Label[EB/OL]. Available at:http://www.accessdata.fda.gov/drug satfda_docs/label/2011/020839s055IbI.pdf. Accessed December,2011.
15. Cattaneo M, Hayward CP, Moffat KA, et al. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry:a report from the platelet physiology subcommittee of the SSC of the ISTH[J]. J Thromb Haemost. 2009 Jun;7(6):1029.
16. Jakubowski JA, Payne CD, Li YG, et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry[J]. Thromb Haemost.2008 Jan;99(1):215-22.
17. Malinin A, Pokov A, Swaim L, et al. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel [J]. Methods Find Exp Clin Pharmacol. 2006 Jun;28(5):315-22.
18. Siller-Matula JM, Delle-Karth G, Lang IM, et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety:the PEGASUS-PCI study[J]. J Thromb Haemost.2012 Apr;10(4):529-42.
19. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J]. JAMA.2009 Aug 26;302(8):849-57.
20. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention:the GRAVITAS randomized trial[J]. JAMA.2011 Mar 16;305(11):1097-105.
21. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting[J]. N Engl J Med.2012 Nov 29;367(22):2100-9.
22. Patrono C. Aspirin as an antiplatelet drug[J]. N Engl J Med.1994 May 5;330(18):1287-94.
23. Jennings LK. Mechanisms of platelet activation:need for new strategies to protect against platelet-mediated atherothrombosis[J], Thromb Haemost.2009 Aug;102(2):248-57.
24. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease[J]. Nat Rev Drug Discov.2010 Feb;9(2):154-69.
25. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary:a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions[J]. Circulation.2001 Jun 19;103(24):3019-41.
26. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology[J]. Eur Heart J.2005 Apr;26(8):804-47.
27.中华医学会心血管病学分会,中华心血管病杂志编辑委员会.经皮冠状动脉介入治疗指南[J].中华心血管病杂志.2002；30(12)：707-718.
28. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-,600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial[J]. Circulation.2005 Nov 8;112(19):2946-50.
29. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes:the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial[J]. J Am Coll Cardiol.2006 Sep 5;48(5):931-8.
30. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7):a randomised factorial trial[J]. Lancet.2010 Oct 9;376(9748):1233-43.
31. Wright RS, Anderson JL, Adams CD, et al.2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons[J]. J Am Coll Cardiol.2011 May 10;57(19):e215-367.
32. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) [J]. Eur Heart J.2011 Dec;32(23):2999-3054.
33.中华医学会心血管病学分会,中华心血管病杂志编辑委员会.经皮冠状动脉介入治疗指南(2009)[J].中华心血管病杂志.2009；37(1)：4-25.
34. Collet JP, Montalescot G. et al. Platelet function testing and implications for clinical practice. J Cardiovasc Pharmacol Ther[J].2009 Sep;14(3):157-69.
35. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial[J]. JAMA.2002 Nov 20;288(19):2411-20.
36. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention) [J]. Circulation.2006 Feb 21;113(7):e166-286.
37.中华医学会心血管病学分会介入心脏病学组,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南2012(简本)[J].中华心血管病杂志.2012；40(4)：271-277.
38. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting:response variability, drug resistance, and the effect of pretreatment platelet reactivity [J]. Circulation.2003 Jun 17;107(23):2908-13.
39. Siller-Matula JM, Haberl K, Prillinger K, et al. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation [J]. Thromb Res. 2009 Apr;123(6):874-80.
40. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J]. Drug Metab Dispos.2010 Jan;38(1):92-9.
41. Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy:2013 update[J]. Clin Pharmacol Ther.2013 Sep;94(3):317-23.
42. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J]. Circulation.2010 Feb 2;121(4):512-8.
43. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J]. JAMA.2009 Aug 26;302(8):849-57.
44. Tantry US, Bliden KP, Wei C, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel:the ONSET/OFFSET and RESPOND genotype studies[J]. Circ Cardiovasc Genet.2010 Dec;3(6):556-66.
45. Frere C, Cuisset T, Gaborit B, et al. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome[J]. J Thromb Haemost.2009 Aug;7(8):1409-11.
46. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation[J]. N Engl J Med.2008 Mar 6;358(10):999-1008.
47. Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention:is the current antiplatelet therapy adequate[J]? J Am Coll Cardiol.2007 Feb 13;49(6):657-66.
48.中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高急性冠状动脉综合征诊断和治疗指南[J].中华心血管病杂志.2012；40(5)：353-67.
49. Ellis SG, Chew D, Chan A, et al. Death following creatine kinase-MB elevation after coronary intervention:identification of an early risk period:importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy[J]. Circulation.2002 Sep 3;106(10):1205-10.
50. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation [J]. JAMA.2010 Feb 24;303(8):754-62.
51. Collet JP, Silvain J, Landivier A, et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose:the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study[J]. Circulation.2008 Sep 16;118(12):1225-33.
52. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med.2007 Nov 15;357(20):2001-15.
53. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med.2009 Sep 10;361(11):1045-57.
54. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals[J]. J Am Coll Cardiol.2005 Jan 18;45(2):246-51.
55. Sofi F, Marcucci R, Gori AM, et al. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis[J]. Thromb Haemost.2010 Apr;103(4):841-8.
56. Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting[J]. J Am Coll Cardiol.2005 May 3;45(9):1392-6.
57. Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis[J]. Am J Cardiol.2009 Jan 1;103(1):5-10.
58. Gurbel PA, Samara WM, Bliden KP. et al. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting:implications for thrombotic events and restenosis[J]. Platelets.2004 Mar;15(2):95-9.
59. Gawaz M, Neumann FJ, Ott I, et al. Changes in membrane glycoproteins of circulating platelets after coronary stent implantation[J]. Heart.1996 Aug;76(2):166-72.
60. Jaster M, Schwimmbeck P, Spencker S, et al. Randomized comparison of platelet-leukocyte aggregates and platelet activation in blood:heparin-coated coiled wire stent implantation versus balloon angioplasty in acute myocardial infarction [J]. Thromb Res.2003;112(5-6):285-9.
61. Bonello L, Harhouri K, Sabatier F, et al. Level of adenosine diphosphate receptor P2Y12 blockade during percutaneous coronary intervention predicts the extent of endothelial injury, assessed by circulating endothelial cell measurement[J]. J Am Coll Cardiol.2010 Sep 21;56(13):1024-31.
62. Siller-Matula JM, Haberl K, Prillinger K, et al. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation[J]. Thromb Res. 2009 Apr;123(6):874-80.
63. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers[J]. PLoS One.2008 Sep 5;3(9):e3148.
64.桂俊豪,田亚平,温新宇等.临床血清循环miRNAs定量技术的建立[J].军医进修学院学报2010 Apr；31(4)：363-6.
65. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma[J]. Br J Haematol.2008 May;141(5):672-5.
66. Landry P, Plante I, Ouellet DL, et al. Existence of a microRNA pathway in anucleate platelets[J]. Nat Struct Mol Biol.2009 Sep;16(9):961-6.
67. Kondkar AA, Bray MS, Leal SM, et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets:suggested role for platelet microRNA[J]. J Thromb Haemost.2010 Feb;8(2):369-78.
68. Shi R, Ge L, Zhou X, et al. Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity [J]. Thromb Res.2013 Jun;131(6):508-13.
69. Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES):a prospective multicentre registry study[J]. Lancet.2013 Aug 17;382(9892):614-23.
70. Price MJ, Coleman JL, Steinhubl SR, et al. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers[J]. Am J Cardiol.2006 Sep 1;98(5):681-4.
71. Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement[J]. J Am Coll Cardiol.2010 Jun 1;55(22):2427-34.
72. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate[J]. J Am Coll Cardiol.2010 Sep 14;56(12):919-33.
73. Siller-Matula JM, Christ G, Lang IM, et al. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay[J]. J Thromb Haemost.2010 Feb;8(2):351-9.
74. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis[J]. J Am Coll Cardiol.2009 Mar 10;53(10):849-56.
75. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med.2009 Jan 22;360(4):363-75.
76. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators[J]. N Engl J Med.1993 Sep 2;329(10):673-82.
77. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects[J]. Blood.2006 Oct 1;108(7):2244-7.
78. Li Y, Tang HL, Hu YF, et al. The gain-of-function variant allele CYP2C19*17:a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients[J]. J Thromb Haemost.2012 Feb;10(2):199-206.
79. Ahmad T, Voora D, Becker RC. The pharmacogenetics of antiplatelet agents:towards personalized therapy[J]? Nat Rev Cardiol.2011 Aug 9;8(10):560-71.
80. Sibbing D, Gebhard D, Koch W, et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy[J]. J Thromb Haemost.2010 Aug;8(8):1685-93.
81. Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment[J]. N Engl J Med.2010 Oct 28;363(18):1704-14.
82. Gurbel PA1, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease[J]. J Am Coll Cardiol.2007 Nov 6;50(19):1822-34.
83. Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets:results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study[J]. Circulation.2005 Mar 8；111(9):1153-9.
84. Mega JL, Hochholzer W, Frelinger AL 3rd, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA.2011 Nov 23;306(20):2221-8.
85. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity:results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study[J]. J Am Coll Cardiol.2009 Mar 31;53(13):1101-9.
86. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes:a genetic substudy of the PLATO trial[J]. Lancet.2010 Oct 16;376(9749):1320-8.
87. Xie X, Ma YT, Yang YN, et al. Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention:a randomized control trial[J]. Int J Cardiol.2013 Oct 9;168(4):3736-40.
88. Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement[J]. Thromb Haemost.2003 May;89(5):783-7.
89. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement[J]. J Am Coll Cardiol.2006 Nov 7;48(9):1742-50.
90. Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention:is the current antiplatelet therapy adequate[J]? J Am Coll Cardiol.2007 Feb 13;49(6):657-66.
1. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents[J]. N Engl J Med.1996 Apr 25;334(17):1084-9.
2. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting:the clopidogrel aspirin stent international cooperative study (CLASSICS) [J]. Circulation.2000 Aug 8;102(6):624-9.
3. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation[J]. N Engl J Med.2005 Mar 24;352(12):1179-89.
4. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J]. N Engl J Med.2001 Aug 16;345(7):494-502.
5. Levine GN, Bates ER, Blankenship JC, et al.2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions[J]. Circulation.2011 Dec 6;124(23):e574-651.
6. Bonello L1, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate[J]. J Am Coll Cardiol.2010 Sep 14;56(12):919-33.
7. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement[J]. J Am Coll Cardiol.2006 Nov 7;48(9):1742-50.
8. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents[J]. J Am Coll Cardiol.2008 May 20;51(20):1925-34.
9. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis[J]. J Am Coll Cardiol.2009 Mar 10;53(10):849-56.
10. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J]. Circulation.2010 Feb 2;121(4):512-8.
11. Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement[J]. J Am Coll Cardiol.2010 Jun 1;55(22):2427-34.
12. Wallentin L. P2Y(12) inhibitors:differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J.2009 Aug;30(16):1964-77.
13. Ding Z, Kim S, Dorsam RT, et al. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270[J]. Blood.2003 May 15;101(10):3908-14.
14. Gachet C. Regulation of platelet functions by P2 receptors [J]. Annu Rev Pharmacol Toxicol.2006;46:277-300.
15. Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway[J]. Pharmacogenet Genomics. 2010 Jul;20(7):463-5.
16. Gremmel T, Steiner S, Seidinger D, et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation[J]. Thromb Haemost.2009 Feb;101(2):333-9.
17. Gremmel T, Steiner S, Seidinger D, et al. Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation[J]. Platelets.2011;22(3):188-95.
18. Paniccia R1, Antonucci E, Gori AM, et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients[J]. J Thromb Haemost.2007 Sep;5(9):1839-47.
19. von Beckerath N, Sibbing D, Jawansky S, et al. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry[J]. Blood Coagul Fibrinolysis.2010 Jan;21(1):46-52.
20. Cattaneo M, Hayward CP, Moffat KA, et al. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry:a report from the platelet physiology subcommittee of the SSC of the ISTH[J]. J Thromb Haemost. 2009 Jun;7(6):1029.
21. Jakubowski JA, Payne CD, Li YG, et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry[J]. Thromb Haemost.2008 Jan;99(1):215-22.
22. Judge HM, Buckland RJ, Sugidachi A, et al. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function[J]. Thromb Haemost.2010 Jun;103(6):1210-7.
23. Malinin A, Pokov A, Swaim L, et al. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel[J]. Methods Find Exp Clin Pharmacol. 2006 Jun;28(5):315-22.
24. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate[J]. J Am Coll Cardiol.2010 Sep 14;56(12):919-33.
25.Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption[J]. Clin Pharmacol Ther.2006 Nov;80(5):486-501.
26. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med.2009 Jan 22;360(4):363-75.
27. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial:a pharmacogenetic analysis[J]. Lancet.2010 Oct 16;376(9749):1312-9.
28. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes:a genetic substudy of the PLATO trial[J]. Lancet.2010 Oct 16;376(9749):1320-8.
29. Luo M, Li J, Xu X, et al. ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients:a meta-analysis[J]. Thromb Res.2012 Jun;129(6):754-9.
30. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J]. Drug Metab Dispos.2010 Jan;38(1):92-9.
31. Steinhubl SR. Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines[J]. Circulation.2010 Feb 2;121(4):481-3.
32. Kubica A, Kozinski M, Grzesk G, et al. Genetic determinants of platelet response to clopidogrel[J]. J Thromb Thrombolysis.2011 Nov;32(4):459-66.
33. Smock KJ, Saunders PJ, Rodgers GM, et al. Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods[J]. Am J Hematol.2011 Dec;86(12):1032-4.
34. Ahmad T, Voora D, Becker RC. The pharmacogenetics of antiplatelet agents:towards personalized therapypy[J]? Nat Rev Cardiol.2011 Aug 9;8(10):560-71.
35. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI:a meta-analysis[J]. JAMA.2010 Oct 27;304(16):1821-30.
36. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J]. Circulation.2010 Feb 2;121(4):512-8.
37. Li Y, Tang HL, Hu YF, et al. The gain-of-function variant allele CYP2C19*17:a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients[J]. J Thromb Haemost.2012 Feb;10(2):199-206.
38. Plavix [package insert] [EB/OL]. Bridgewater, NJ:Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; 2011.
39. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention[J]. Eur Heart J.2009 Apr;30(8):916-22.
40. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel[J]. N Engl J Med.2009 Jan 22;360(4):354-62.
41. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration:a systematic meta-analysis[J]. J Am Coll Cardiol.2010 Jul 6;56(2):134-43.
42. Bouman HJ, Schomig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy[J]. Nat Med.2011 Jan;17(1):110-6.
43. Fontana P, James R, Barazer I, et al. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study[J]. J Thromb Haemost.2011 Aug;9(8):1664-6.
44. Lewis JP, Fisch AS, Ryan K, et al. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response[J]. Clin Pharmacol Ther.2011 Oct;90(4):568-74.
45. Sibbing D, Koch W, Massberg S, et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting[J]. Eur Heart J.2011 Jul;32(13):1605-13.
46. Shuldiner AR1, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J]. JAMA.2009 Aug 26;302(8):849-57.
47. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease [J]. Thromb Res.2005;116(6):491-7.
48. Ishizaki T, Horai Y. Review article:cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole[J]. Aliment Pharmacol Ther.1999 Aug;13 Suppl 3:27-36.
49. Horn J. Review article:relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole[J]. Aliment Pharmacol Ther.2004 Nov;20 Suppl 6:11-9.
50. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin:the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study[J]. J Am Coll Cardiol.2008 Jan 22;51(3):256-60.
51. Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study[J]. J Am Coll Cardiol.2009 Sep 22;54(13):1149-53.
52. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel [J]. Am Heart J.2009 Jan;157(1):148.e1-5.
53. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med.2009 Jan 22;360(4):363-75.
54. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors:a cohort study[J]. Ann Intern Med.2010 Mar 16;152(6):337-45.
55. Kwok CS, Loke YK. Meta-analysis:the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel [J]. Aliment Pharmacol Ther.2010 Apr;31(8):810-23.
56. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease[J]. N Engl J Med.2010 Nov 11;363(20):1909-17.
57. Levine GN, Bates ER, Blankenship JC, et al.2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions[J]. Circulation.2011 Dec 6;124(23):e574-651.
58. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase[J]. Science.2001 May 11;292(5519):1160-4.
59. Bellosta S1, Paoletti R, Corsini A. Safety of statins:focus on clinical pharmacokinetics and drug interactions[J]. Circulation.2004 Jun 15;109(23 Suppl 1):III50-7.
60. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin[J]. Drug Metab Dispos.2003 Jan;31(1):53-9.
61. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation:a new drug-drug interaction[J]. Circulation.2003 Jan 7;107(1):32-7.
62. Muller I, Besta F, Schulz C, et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel[J]. Circulation.2003 Nov 4;108(18):2195-7.
63. Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial[J]. Circulation.2003 Aug 26;108(8):921-4.
64. Lim MJ, Spencer FA, Gore JM, et al. Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes:perspectives from a large multinational registry[J]. Eur Heart J.2005 Jun;26(11):1063-9.
65. Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies[J]. Am J Cardiol.2003 Aug 1;92(3):285-8.
66. Saw J, Brennan DM, Steinhubl SR, et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial[J]. J Am Coll Cardiol.2007 Jul 24;50(4):291-5.
67. Siller-Matula JM, Lang I, Christ G, et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel[J]. J Am Coll Cardiol.2008 Nov 4;52(19):1557-63.
68. Olesen JB, Gislason GH, Chariot MG, et al. Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction:a nationwide cohort study[J]. J Am Coll Cardiol.2011 Jan 25;57(4):409-17.
69. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J]. Circulation.2010 Feb 2;121(4):512-8.
70. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med.2009 Jan 22;360(4):363-75.
71. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment[J]. Diabetes.2005 Aug;54(8):2430-5.
72. Angiolillo DJ, Bernardo E, Ramirez C, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment[J]. J Am Coll Cardiol.2006 Jul 18;48(2):298-304.
73. Ferroni P, Basili S, Falco A, et al. Platelet activation in type 2 diabetes mellitus[J]. J Thromb Haemost.2004 Aug;2(8):1282-91.
74. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance:an emerging clinical entity[J]. Eur Heart J.2006 Mar;27(6):647-54.
75. Gawaz M, Neumann FJ, Ott I, et al. Platelet function in acute myocardial infarction treated with direct angioplasty[J]. Circulation.1996 Jan 15;93(2):229-37.
76. Serebruany VL, Malinin Al, Jerome SD, et al. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure:the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial[J]. Am Heart J.2003 Oct; 146(4):713-20.
77. Soffer D, Moussa I, Harjai KJ, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention:do we need more aggressive dosing regimens in unstable angina[J]? Catheter Cardiovasc Interv.2003 May;59(1):21-5.
78. Siller-Matula JM, Haberl K, Prillinger K, et al. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation[J]. Thromb Res. 2009 Apr;123(6):874-80.
79. CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes[J]. N Engl J Med.2010 Sep 2;363(10):930-42.
80. Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI[J]. JAMA.2011 Sep 21;306(11):1215-23.
81. Price MJ, Berger PB, Teirstein PS, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention:the GRAVITAS randomized trial[J]. JAMA.2011 Mar 16;305(11):1097-105.
82. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting[J]. N Engl J Med.2012 Nov 29;367(22):2100-9.
83. FDA Drug Safety Communication:reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug[EB/OL]. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatients and Providers/ucm203888.htm. Accessed April 28,2010.
84. GIANT ongoing trial-US National Library of Medicine[EB/OL]. ClinicalTrials.gov. http://clinicaltrial.gov/ct2/show/NCT01134380(2010) Accessed November 10,2011.
85. GeCCo ongoing trial-US National Library of Medicine[EB/OL]. ClinicalTrials.gov. http://clinicaltrial.gov/ct2/show/NCT00995514(2009). Accessed November 10, 2011.
86. RAPID-STEMI ongoing trial-US National Library of Medicine[EB/OL]. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT01452139(2011) Accessed January 3,2012.
87. Mega JL, Hochholzer WFrelinger AL 3rd, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease[J]. JAMA.2011 Nov 23;306(20):2221-8.
88. Michelson AD, Frelinger AL 3rd, Braunwald E, et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial[J]. Eur Heart J.2009 Jul;30(14):1753-63.
89. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med.2007 Nov 15;357(20):2001-15.
90. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med.2009 Sep 10;361(11):1045-57.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |